New narcolepsy drug tested in tiny trial – but study halted early
NCT ID NCT06961266
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested an experimental drug called JZP441 in just 6 adults with narcolepsy type 1, a condition that causes sudden daytime sleepiness. The goal was to see if the drug could help people stay awake longer, as measured by a standard sleep test. However, the study was terminated early, so we have limited information on how well it worked or its safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
JZP441 (an oral drug)
What this could lead to
If it works, this could point toward a new treatment to help people with narcolepsy stay awake during the day.
What could go wrong
This is a very early, tiny trial (only 6 people) that was terminated, so results are limited. The drug may not work or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NARCOLEPSY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Trial Site
Atlanta, Georgia, 30328, United States
-
Clinical Trial Site
Cincinnati, Ohio, 45245, United States
-
Clinical Trial Site
Columbia, South Carolina, 29201, United States
-
Clinical Trial Site
Austin, Texas, 78731, United States